TY - JOUR
T1 - Omega-3 fatty acids ameliorate proteinuria but not renal function in iga nephropathy
T2 - A meta-analysis of randomized controlled trials
AU - Chou, Hsin Hsu
AU - Chiou, Yuan Yow
AU - Hung, Peir Haur
AU - Chiang, Pei Chung
AU - Wang, Shan Tair
PY - 2012/12/1
Y1 - 2012/12/1
N2 - Background/Aim: The effects of ω-3 fatty acids (O3FAs) on renal function and proteinuria in immunoglobulin A nephropathy (IgAN) are not fully understood. Thus, we conducted an up-to-date meta-analysis of the currently available randomized controlled trials (RCTs) to validate the effects of O3FA in IgAN. Methods: A literature search was performed in PubMed, Medline, Embase and the Cochrane Central Registry of Controlled Trials using an extended search strategy to identify RCTs that assessed the treatment efficacy of O3FA in IgAN. The dose-effect relationships of O3FA on renal function and proteinuria were also determined. Results: Five RCTs with a total of 233 patients were included in our analysis. Our results demonstrated that while O3FA does not have any beneficial effects in preserving renal function in IgAN, proteinuria was significantly reduced. Furthermore, patients who received a high dose of O3FA (>3 g/day) did not differ from those who received a low dose of O3FA (≤3 g/day) in renal function or proteinuria. Conclusion: The currently available evidence suggests that O3FA has no benefit in preserving renal function, but can ameliorate proteinuria in IgAN. However, the effects of O3FA on proteinuria are not dose dependent.
AB - Background/Aim: The effects of ω-3 fatty acids (O3FAs) on renal function and proteinuria in immunoglobulin A nephropathy (IgAN) are not fully understood. Thus, we conducted an up-to-date meta-analysis of the currently available randomized controlled trials (RCTs) to validate the effects of O3FA in IgAN. Methods: A literature search was performed in PubMed, Medline, Embase and the Cochrane Central Registry of Controlled Trials using an extended search strategy to identify RCTs that assessed the treatment efficacy of O3FA in IgAN. The dose-effect relationships of O3FA on renal function and proteinuria were also determined. Results: Five RCTs with a total of 233 patients were included in our analysis. Our results demonstrated that while O3FA does not have any beneficial effects in preserving renal function in IgAN, proteinuria was significantly reduced. Furthermore, patients who received a high dose of O3FA (>3 g/day) did not differ from those who received a low dose of O3FA (≤3 g/day) in renal function or proteinuria. Conclusion: The currently available evidence suggests that O3FA has no benefit in preserving renal function, but can ameliorate proteinuria in IgAN. However, the effects of O3FA on proteinuria are not dose dependent.
UR - http://www.scopus.com/inward/record.url?scp=84871667302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871667302&partnerID=8YFLogxK
U2 - 10.1159/000341929
DO - 10.1159/000341929
M3 - Article
C2 - 23095320
AN - SCOPUS:84871667302
VL - 121
SP - c30-c35
JO - Nephron - Clinical Practice
JF - Nephron - Clinical Practice
SN - 1660-2110
IS - 1-2
ER -